Safety and Immunogenicity of Influenza H9 Vaccine in Humans

NCT00814229 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

353

Enrollment

OTHER

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: H9N2 whole virus vaccine, IM, 1.5microg
BIOLOGICAL: H9N2 whole virus vaccine, IM, 5microg
BIOLOGICAL: H9N2 whole virus vaccine vaccine, IM, 15microg
BIOLOGICAL: H9N2 whole virus vaccine, IM, 45microg
BIOLOGICAL: H9N2 whole virus vaccine, alum, IM, 1.5microg
BIOLOGICAL: H9N2 whole virus, alum, IM, 5microg
BIOLOGICAL: H9N2 vaccine, whole virus, alum, IM, 15 microg
BIOLOGICAL: H9N2 vaccine, whole virus, alum, IM, 45microg
BIOLOGICAL: H9N2 virosome vaccine, IM, 1.5microg
BIOLOGICAL: H9N2 virosomal vaccine, IM, 5microg
BIOLOGICAL: H9N2 virosomal vaccine, IM, 15microg
BIOLOGICAL: H9N2 virosomal vaccine, IM, 45microg
BIOLOGICAL: H9N2 whole virus vaccine, ID, 5microg
BIOLOGICAL: H9N2 whole virus vaccine, ID, 15microg

Sponsor

University Hospitals, Leicester

Collaborators

[object Object]
[object Object]
[object Object]